Value-Based Cancer Care Issues

July/August 2010, Vol 1, No 3

Individualizing Colorectal Cancer Care through Genetics

Annual ONS Congress

San Diego, CA—Three nurse researchers from the Oncology Nursing Society (ONS) Cancer Genetics Special Interest Group shared how the results of genetic testing conducted within the care setting are individualizing—and improving—care for colorectal cancer (CRC) at a session at the Annual ONS Congress. Beginning with an [ Read More ]

Do End-of-Life Products Deserve Special Treatment?

ISPOR Annual Meeting

Atlanta, GA—Echoes of the recent contentious American debate over healthcare could be clearly heard in a session at the meeting of the International Society for Pharmacoeconomics and Outcomes Research that addressed issues surrounding the funding of new treatments, technologies, and drugs for patients nearing the end of the [ Read More ]

Cost Considerations Change Dialogue

ASCO Annual Meeting

Although financial concerns are increasingly influencing choices in cancer therapy, barriers to cost discussions between physicians and patients often limit the scope of such discussions. Incentives for oncologists to use high-cost interventions and patients’ perceptions that cost consideration equates to second-class care are but 2 barriers to meaningful cost [ Read More ]

The New Face of the Community Oncology Practice


Community oncologists are facing big changes to the way they have traditionally practiced, and they would be wise to accept, adapt, and move on, speakers said at a session at the 2010 ASCO annual meeting titled “The Challenge of Financial Survival.” Economic pressures are essentially killing many [ Read More ]

Pathway Compliance Reduces Drug, Nondrug Expenses


Evaluation of a regional payer-based pay-for-quality (P4Q) oncology program showed that Pathways programs can greatly reduce the cost of cancer care by slowing the growth rate of both drug and nondrug expenses. Although oncology clinical Pathways are common in current practice, there has been little [ Read More ]

Comparative Effectiveness Research Will Help Guide Health Policy


The cost of caring for cancer rose from $27 billion in 2009 to $90 billion in 2008, yet unwarranted variation in that care persists across centers, providers, and patients. As yet, there is little evidence on comparative effectiveness of the different management options and on the value provided [ Read More ]

Reasons for Breast Cancer Care Disparities Remain Unclear


Chicago, IL—Insurance status and socioeconomic status (SES) explain little of the racial and ethnic variation in the receipt of recommended therapy for breast cancer, found Rachel Freedman, MD, MPH, in her examination of a national cancer registry. She sought to determine the variables that might explain differences [ Read More ]

Adherence to Colon Cancer Chemotherapy Guidelines Depends on Treatment Setting


When treating patients with colon cancer in the community oncology setting, adherence to evidence-centered guidelines for the use of chemotherapy regimens varies by setting, with adherence rates higher in the adjuvant setting and somewhat lower in the metastatic setting, said McKesson Specialty Care Solutions’ Zhaohui Wang, MD, PhD, at [ Read More ]

How Will Costs Be Contained in the New Healthcare Environment?


Prospective payment and bundling of payments offer the most promising means to contain healthcare costs, said David O. Meltzer, MD, PhD, who gave a rundown of the weaknesses and strengths of some of the proposed remedies to reel in healthcare costs in the postreform United States. He made [ Read More ]

Clinical Trials: Understanding Cost, Coverage Implications


San Diego, CA—Emphasizing the costs and financial reimbursement issues associated with the “everchanging, ever-complex environment” of clinical trial research, a session at the 35th Annual Oncology Nursing Society (ONS) Congress addressed a crowd of both current clinical trial nurses and attendees who may take on this role, discussing [ Read More ]

Medicare, a Major P(l)ayer, Not Ready for New Payment Policy Evidence


Atlanta, GA—A session at the 2010 meeting of the International Society for Pharmacoeconomics and Outcomes Research discussing how Medicare’s evidence requirements for covering new technologies might change under the new healthcare reform bill painted a portrait of an agency that has recently raised the evidentiary standards for evaluating [ Read More ]

Moving Targets: Personalized Medicine and Targeted Therapies


Atlanta, GA—Even as the development of targeted therapies has advanced rapidly in the past several years, the evidence base, evaluation, and reimbursement structures surrounding the use of these products in the real world have lagged behind. A panel presenting research, governmental, and private payer perspectives discussed these issues, and [ Read More ]